Keymed Biosciences announces 2022 annual results: Efficiently driving clinical progress and proactively expanding global strategic collaboration

CHENGDU, China, 18. März 2023 /PRNewswire/-- Keymed Biosciences Inc. (HKEX: 02162) gab seine Jahrergebnisse für 2022 bekannt.

Related Keywords

Guangzhou ,Guangdong ,China ,Chengdu ,Sichuan ,Jinan ,Shandong ,Shanghai ,United States ,Hong Kong ,Shenzhen ,Beijing ,Wuhan ,Hubei ,Nanjing ,Jiangsu ,Keymed Bio ,Biosciences Inc ,Keymed Biosciences Inc ,Keymed Biosciences ,Breakthrough Therapy Designation ,Drug Designation ,Fast Track Designation ,Shenzhen Hong Kong Stock ,Small Cap Index ,Small Cap ,Main Board ,Hong Kong Stock Exchange ,